title: Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas.
abstract: Allo-SCT is regularly performed in advanced lymphoma. Haploidentical family donors are a valuable source of hematopoietic stem cells and transplants from these donors, using T-repleted grafts, has recently been successfully reported. We report on 49 patients with refractory lymphoma who received T-repleted haploidentical SCT with a non-myeloablative regimen and post-transplant CY. The median time to recover ANC >0.5 × 10e9/L and transfusion independent plt count >20 × 10e9/L was 20 days (range 14-38) and 26 days (range 14-395). The probability to reach ANC >0.5 × 10e9/L at 30 days was 87% and transfusion independent plt count >20 × 10e9/L at 100 days was 87%. The cumulative incidence of grade 2-4 acute GVHD (aGVHD) was 25.6% (95% confidence interval (CI): 12.9-38.3%) and the cumulative incidence of chronic GVHD (cGVHD) was 5.2% (95% CI: 0-12.4%). The median follow-up is 20.6 months (range 12-54), and the projected 2-year OS and PFS were 71 and 63%. The relapse rate was 18.7% (95% CI: 7.6-29.8%) and the median time to relapse was 4.4 months (range 1.1-8.3). At 2 years, cumulative incidence of NRM was 16.3% (95% CI: 5.9-26.8%). T-repleted Haploidentical transplantation with post-infusion CY is a feasible and effective therapy in the poor prognosis of advanced lymphoma patients.
authors.affiliation: 1] Hematology Department, Humanitas Cancer Center, Istituto Clinico Humanitas, Milan, Italy [2] Hematology Department, Institut Paoli Calmettes 232, Boulevard S Marguerite, Marseille, France.
authors.forename: L
authors.initials: L
authors.lastname: Castagna
authors.affiliation: Hematology Department, Humanitas Cancer Center, Istituto Clinico Humanitas, Milan, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Bramanti
authors.affiliation: Hematology Department, Institut Paoli Calmettes 232, Boulevard S Marguerite, Marseille, France.
authors.forename: S
authors.initials: S
authors.lastname: Furst
authors.affiliation: Hematology Department, Humanitas Cancer Center, Istituto Clinico Humanitas, Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Giordano
authors.affiliation: Hematology Department, Institut Paoli Calmettes 232, Boulevard S Marguerite, Marseille, France.
authors.forename: R
authors.initials: R
authors.lastname: Crocchiolo
authors.affiliation: Hematology Department, Humanitas Cancer Center, Istituto Clinico Humanitas, Milan, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Sarina
authors.affiliation: Hematology Department, Humanitas Cancer Center, Istituto Clinico Humanitas, Milan, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Mauro
authors.affiliation: Hematology Department, Humanitas Cancer Center, Istituto Clinico Humanitas, Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Morabito
authors.affiliation: Hematology Department, Institut Paoli Calmettes 232, Boulevard S Marguerite, Marseille, France.
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.affiliation: Hematology Department, Institut Paoli Calmettes 232, Boulevard S Marguerite, Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Coso
authors.affiliation: Hematology Department, Humanitas Cancer Center, Istituto Clinico Humanitas, Milan, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Balzarotti
authors.affiliation: Hematology Department, Institut Paoli Calmettes 232, Boulevard S Marguerite, Marseille, France.
authors.forename: F
authors.initials: F
authors.lastname: Broussais
authors.affiliation: Hematology Department, Institut Paoli Calmettes 232, Boulevard S Marguerite, Marseille, France.
authors.forename: J
authors.initials: J
authors.lastname: El-Cheikh
authors.affiliation: Hematology Department, Humanitas Cancer Center, Istituto Clinico Humanitas, Milan, Italy.
authors.forename: C C
authors.initials: CC
authors.lastname: Stella
authors.affiliation: Hematology Department, Humanitas Cancer Center, Istituto Clinico Humanitas, Milan, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Brusamolino
authors.affiliation: Hematology Department, Institut Paoli Calmettes 232, Boulevard S Marguerite, Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.affiliation: Hematology Department, Humanitas Cancer Center, Istituto Clinico Humanitas, Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Santoro
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D016130:Immunophenotyping; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000150:complications; D010976:Platelet Count; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome